Affymax Reviews

8 Reviews
8 Reviews
Rating Trends

Recommend to a friend
Approve of CEO
Affymax CEO and Director John Orwin
John Orwin
1 Rating

    Great place to work, but didn't focus enough on pipeline for future

    • Comp & Benefits
    • Work/Life Balance
    • Senior Management
    • Culture & Values
    • Career Opportunities
    Former Employee - Affymax  in  Palo Alto, CA (US)
    Former Employee - Affymax in Palo Alto, CA (US)

    I worked at Affymax as a contractor for less than a year


    great co-workers and management. also great culture and work/life balance


    no investment in R&D for future pipeline

    Advice to ManagementAdvice

    focus on the pipeline in the future

    Negative Outlook
    No opinion of CEO

Affymax Interviews

Interview Experience

Interview Experience


Getting an Interview

Getting an Interview


Interview Difficulty


Interview Difficulty




    Research Associate Interview

    Anonymous Interview Candidate
    Anonymous Interview Candidate
    Application Details

    I applied online. The process took a day - interviewed at Affymax.

    Interview Details

    All day interview with 8 scientists and 4 technicians. Thorough assessment of all technical skills and academic experience. Very attentive audience at presentation with insightful questions. Beautiful facilities and support services. Supervisor stressed intellectual-minded faculty and opportunity to conduct self-directed research.

    Interview Questions
    • How have you demonstrated ability to solve difficult problems in the lab and with other scientists?   Answer Question
    Accepted Offer

Affymax Awards and Accolades

Let us know if we're missing any workplace or industry recognition – Add an award

Additional Info

Unlock Profile
Headquarters Palo Alto, CA
Size 16 to 50 Employees
Founded 2001
Type Company - Public
Industry Biotech & Pharmaceuticals
Revenue £1 to £5 million (GBP) per year
Competitors Amgen, Janssen Biotech, Roche

Affymax is designing peptides to give red blood cells a pep talk. The biotechnology firm is researching and developing possible drugs based upon these biological process regulators. Its leading drug candidate, Hematide, is an erythropoietin (EPO) mimetic, designed to stimulate red blood cell production, like EPO itself. Hematide is being investigated in late stage clinical trials as a possible treatment for anemia caused by chronic renal failure and chemotherapy. Affymax believes Hematide will be cheaper and longer lasting than the EPO stimulants currently used on dialysis... More

Worked for Affymax? Contribute to the Community!